Market Cap 112.31B
Revenue (ttm) 48.19B
Net Income (ttm) 7.05B
EPS (ttm) N/A
PE Ratio 9.36
Forward PE 8.78
Profit Margin 14.64%
Debt to Equity Ratio 2.21
Volume 15,981,400
Avg Vol 11,586,804
Day's Range N/A - N/A
Shares Out 2.04B
Stochastic %K 47%
Beta 0.24
Analysts Sell
Price Target $62.88

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unres...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 609 252 4621
Website: www.bms.com
Address:
Route 206 & Province Line Road, Princeton, United States
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 26 at 12:10 PM
$SLS $BMY $MRK $PFE Part 2. galinpepimut-S (GPS) is an immunotherapy that trains the patient's own immune system to hunt down residual cancer cells expressing the WT1 protein. GPS offers a "favorable" profile because it targets cancer cells specifically with minimal toxicity - because it is an immunotherapeutic, side effects are primarily low-grade local injection site reactions (redness/mild pain). • No Myelosuppression: Unlike Onureg, GPS does not suppress the bone marrow. This is a critical advantage for AML patients who already have fragile blood counts. • Preserved Quality of Life: Patients generally do not experience the daily fatigue or GI distress associated with oral maintenance chemotherapy. GPS efficacy does not come at the cost of quality of life. GPS has been shown to be very safe, with 0 Toxicity and CURATIVE efficacy. ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 26 at 11:31 AM
$ABBV $BMY $MRK $PFE $SLS Potential T1 halt before Material News. 63 Million SLS Short position trapped As of 2026-06-26 07:17:11 AM EDT, there were 35,000 shares available with a fee of 188.75%. ✌️🙏❤️‍🩹
0 · Reply
TalkMarkets
TalkMarkets Jun. 26 at 8:22 AM
Dividend Stock Analysis: Johnson & Johnson (JNJ) $JNJ $ABBV $LLY $BMY https://talkmarkets.com/article/dividend-stock-analysis-johnson-johnson-jnj-1782462113
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 26 at 1:48 AM
$SLS $PFE $BMY $ABBV $MRK 5. Fast Track Designation • Indications: AML, MPM, and MM. • Details: Expedites the FDA review and development process for drugs treating serious conditions that fill unmet medical needs. 6. 3 Priority Review Vouchers worth $450 Million Dollars at current market rates for PRV’s for big pharmaceutical suitors. 7. 4 of the most powerful companies in oncology all have specific strategic reasons to own GPS after a positive REGAL phase 3 readout. BMS needs to protect Onureg. AbbVie needs to protect Venetoclax. Merck needs to extend Keytruda past the patent cliff. And Pfizer just hired people who came from the exact companies that GPS is about to disrupt and know precisely what that disruption is worth= $240.00+ after Bidding War. REGAL phase 3 Paradigm Shifting data is about to delivers perhaps the most consequential and contested acquisition in Biotechnology sector has seen in a generation. ***Change of Control filed today, all the pieces are now in place. ✌️🙏❤️‍🩹
1 · Reply
JuggernautRaider
JuggernautRaider Jun. 26 at 1:08 AM
$AVXL presidents get replaced every 4 years in America 😂 Why should little old Avanex be any different? $BMY $CGTX $TLSA 🧠
0 · Reply
Quantumup
Quantumup Jun. 25 at 9:03 PM
Oppenheimer🏁 $EPRX OP-$17 $PHAT $BMY AZN-AMGN APGE-ABBV Oppenheimer said—We initiate coverage of Eupraxia Pharmaceuticals with an Outperform rating and $17 PT, reflecting the differentiated potential for lead asset EP-104GI in eosinophilic esophagitis (EoE), an underappreciated indication dominated by burdensome steroids and high-cost biologics. By delivering sustained, localized fluticasone via a once-yearly endoscopic procedure, EP-104GI appears well-positioned to address a significant treatment gap where adherence remains critically challenging, supported by KOL feedback and prior Ph1b/2a data showing durable remission and promising safety. Ph2b interim data in 4Q26 is the next pivotal catalyst, where positive data, similar to Ph1b/2a, could unlock ~50% upside and support Ph3 initiation within current cash runway (~$140M into 2H28E). We forecast peak risk-adjusted EoE sales of $1.2B, following commercialization in 2031, and view Gl indication expansion as potential additional upside.
0 · Reply
srapp123
srapp123 Jun. 25 at 7:16 PM
$BMY why is this lagging the broader healthcare sector?
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 25 at 4:20 PM
$SLS $ABVX $GLSI after Many YEARS of the Most Rank Market Manipulation, we are now about to Discover and Realize the TRUE VALUE of GPS - a Revolutionary AML Remision Maintenance Immunotherapy that Prevents Relapse and Extends Survival for over 100,000 Patients Currently in Remission. $28B TAM FDA TYPE C manufacture already approved Pristine Safety Profile Indefinite Dosing to Relapse 5 years / Compounded Revenue FDA / EU Orphan / Fast Track / RPRV IP rights to 2037 $MRK $BMY Partnerships 009 Secondary Asset with $5B Comps. IMMINENT 80th EVENT ANNNOUNCEMENT and Phase 3 Results 5 years in the Making...
0 · Reply
Quantumup
Quantumup Jun. 25 at 1:14 PM
Raymond James y'day🏁 $MPLT and said: We are initiating coverage of MapLight Therapeutics (MPLT) at Strong Buy with a $46 target price. $BMY OTSKY ABBV NBIX LBRX RVPH ATAI TEVA ITCI Here's what Raymond James had to say: https://x.com/Quantumup1/status/2070133195882836133?s=20
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 24 at 7:12 PM
$SLS SMART Money will be Surging into Position on the 80th Event PR --- 80th Event and Share Price Launch now truly Imminent. - the reason the Share Price Launched on each of the Previous Event PR's, is the Same Reason, it will Just about double to $18/ $20 on the 80th. That is - SMART MONEY ... Much Smarter than US ( $ABBV / $RHHBY $BMY) Knows BAT does not offer effective Remission Maintenance - they Know its Gps Doing what its done in all 7 Prior Trials - Prevent Relapse and Extend Survival - Directly Correlated with Immune Response- SMART Money will be Surging into Position on the 80th Event PR --- 80th Event and Share Price Launch now truly Imminent. The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA From the INTERIM ANALYSIS at 60 Events.. - penny flipping idiots are going regret for the rest of their Miserable Short Lives, for selling for anything less than $100 Per Share - now you know.
0 · Reply
Latest News on BMY
Bristol Myers Squibb Announces Dividend

Jun 17, 2026, 4:16 PM EDT - 8 days ago

Bristol Myers Squibb Announces Dividend


The Healthcare M&A Wave

Jun 17, 2026, 12:30 PM EDT - 8 days ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX


3 Stocks to Invest In to Rebalance Your Portfolio

Jun 17, 2026, 12:00 PM EDT - 8 days ago

3 Stocks to Invest In to Rebalance Your Portfolio

CLX LMT


Bristol Myers says FDA accepts sNDA for Camzyos

2026-06-01T11:15:21.000Z - 25 days ago

Bristol Myers says FDA accepts sNDA for Camzyos


C4 Therapeutics jumps after Bristol Myers myeloma data

2026-05-29T15:51:38.000Z - 27 days ago

C4 Therapeutics jumps after Bristol Myers myeloma data

CCCC


Bristol Myers announces strategic agreement with Anthropic

2026-05-20T11:00:11.000Z - 5 weeks ago

Bristol Myers announces strategic agreement with Anthropic


Bristol-Myers Squibb and China's Hengrui Pharma Forge Tie-Up

May 12, 2026, 2:35 AM EDT - 6 weeks ago

Bristol-Myers Squibb and China's Hengrui Pharma Forge Tie-Up


Bristol-Myers Squibb Company Transcript: AGM 2026

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Bristol-Myers Squibb Company Transcript: AGM 2026


Bristol-Myers Squibb Company Earnings Call Transcript: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Bristol-Myers Squibb Company Earnings Call Transcript: Q1 2026


Bristol-Myers Squibb Company Earnings release: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Bristol-Myers Squibb Company Earnings release: Q1 2026


Bristol-Myers Squibb Company Slides: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Bristol-Myers Squibb Company Slides: Q1 2026


Bristol-Myers Squibb Company Quarterly report: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Bristol-Myers Squibb Company Quarterly report: Q1 2026


Bristol Myers Squibb Logs Higher Sales, Profit

Apr 30, 2026, 7:11 AM EDT - 2 months ago

Bristol Myers Squibb Logs Higher Sales, Profit


Bristol-Myers Squibb Company Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Bristol-Myers Squibb Company Proxy statement: Proxy filing


Bristol-Myers Squibb Company Proxy statement: Proxy filing

Mar 25, 2026, 8:00 AM EDT - 3 months ago

Bristol-Myers Squibb Company Proxy statement: Proxy filing


Bristol-Myers Squibb Company Proxy statement: Proxy filing

Mar 25, 2026, 8:00 AM EDT - 3 months ago

Bristol-Myers Squibb Company Proxy statement: Proxy filing


SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 26 at 12:10 PM
$SLS $BMY $MRK $PFE Part 2. galinpepimut-S (GPS) is an immunotherapy that trains the patient's own immune system to hunt down residual cancer cells expressing the WT1 protein. GPS offers a "favorable" profile because it targets cancer cells specifically with minimal toxicity - because it is an immunotherapeutic, side effects are primarily low-grade local injection site reactions (redness/mild pain). • No Myelosuppression: Unlike Onureg, GPS does not suppress the bone marrow. This is a critical advantage for AML patients who already have fragile blood counts. • Preserved Quality of Life: Patients generally do not experience the daily fatigue or GI distress associated with oral maintenance chemotherapy. GPS efficacy does not come at the cost of quality of life. GPS has been shown to be very safe, with 0 Toxicity and CURATIVE efficacy. ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 26 at 11:31 AM
$ABBV $BMY $MRK $PFE $SLS Potential T1 halt before Material News. 63 Million SLS Short position trapped As of 2026-06-26 07:17:11 AM EDT, there were 35,000 shares available with a fee of 188.75%. ✌️🙏❤️‍🩹
0 · Reply
TalkMarkets
TalkMarkets Jun. 26 at 8:22 AM
Dividend Stock Analysis: Johnson & Johnson (JNJ) $JNJ $ABBV $LLY $BMY https://talkmarkets.com/article/dividend-stock-analysis-johnson-johnson-jnj-1782462113
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 26 at 1:48 AM
$SLS $PFE $BMY $ABBV $MRK 5. Fast Track Designation • Indications: AML, MPM, and MM. • Details: Expedites the FDA review and development process for drugs treating serious conditions that fill unmet medical needs. 6. 3 Priority Review Vouchers worth $450 Million Dollars at current market rates for PRV’s for big pharmaceutical suitors. 7. 4 of the most powerful companies in oncology all have specific strategic reasons to own GPS after a positive REGAL phase 3 readout. BMS needs to protect Onureg. AbbVie needs to protect Venetoclax. Merck needs to extend Keytruda past the patent cliff. And Pfizer just hired people who came from the exact companies that GPS is about to disrupt and know precisely what that disruption is worth= $240.00+ after Bidding War. REGAL phase 3 Paradigm Shifting data is about to delivers perhaps the most consequential and contested acquisition in Biotechnology sector has seen in a generation. ***Change of Control filed today, all the pieces are now in place. ✌️🙏❤️‍🩹
1 · Reply
JuggernautRaider
JuggernautRaider Jun. 26 at 1:08 AM
$AVXL presidents get replaced every 4 years in America 😂 Why should little old Avanex be any different? $BMY $CGTX $TLSA 🧠
0 · Reply
Quantumup
Quantumup Jun. 25 at 9:03 PM
Oppenheimer🏁 $EPRX OP-$17 $PHAT $BMY AZN-AMGN APGE-ABBV Oppenheimer said—We initiate coverage of Eupraxia Pharmaceuticals with an Outperform rating and $17 PT, reflecting the differentiated potential for lead asset EP-104GI in eosinophilic esophagitis (EoE), an underappreciated indication dominated by burdensome steroids and high-cost biologics. By delivering sustained, localized fluticasone via a once-yearly endoscopic procedure, EP-104GI appears well-positioned to address a significant treatment gap where adherence remains critically challenging, supported by KOL feedback and prior Ph1b/2a data showing durable remission and promising safety. Ph2b interim data in 4Q26 is the next pivotal catalyst, where positive data, similar to Ph1b/2a, could unlock ~50% upside and support Ph3 initiation within current cash runway (~$140M into 2H28E). We forecast peak risk-adjusted EoE sales of $1.2B, following commercialization in 2031, and view Gl indication expansion as potential additional upside.
0 · Reply
srapp123
srapp123 Jun. 25 at 7:16 PM
$BMY why is this lagging the broader healthcare sector?
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 25 at 4:20 PM
$SLS $ABVX $GLSI after Many YEARS of the Most Rank Market Manipulation, we are now about to Discover and Realize the TRUE VALUE of GPS - a Revolutionary AML Remision Maintenance Immunotherapy that Prevents Relapse and Extends Survival for over 100,000 Patients Currently in Remission. $28B TAM FDA TYPE C manufacture already approved Pristine Safety Profile Indefinite Dosing to Relapse 5 years / Compounded Revenue FDA / EU Orphan / Fast Track / RPRV IP rights to 2037 $MRK $BMY Partnerships 009 Secondary Asset with $5B Comps. IMMINENT 80th EVENT ANNNOUNCEMENT and Phase 3 Results 5 years in the Making...
0 · Reply
Quantumup
Quantumup Jun. 25 at 1:14 PM
Raymond James y'day🏁 $MPLT and said: We are initiating coverage of MapLight Therapeutics (MPLT) at Strong Buy with a $46 target price. $BMY OTSKY ABBV NBIX LBRX RVPH ATAI TEVA ITCI Here's what Raymond James had to say: https://x.com/Quantumup1/status/2070133195882836133?s=20
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 24 at 7:12 PM
$SLS SMART Money will be Surging into Position on the 80th Event PR --- 80th Event and Share Price Launch now truly Imminent. - the reason the Share Price Launched on each of the Previous Event PR's, is the Same Reason, it will Just about double to $18/ $20 on the 80th. That is - SMART MONEY ... Much Smarter than US ( $ABBV / $RHHBY $BMY) Knows BAT does not offer effective Remission Maintenance - they Know its Gps Doing what its done in all 7 Prior Trials - Prevent Relapse and Extend Survival - Directly Correlated with Immune Response- SMART Money will be Surging into Position on the 80th Event PR --- 80th Event and Share Price Launch now truly Imminent. The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA From the INTERIM ANALYSIS at 60 Events.. - penny flipping idiots are going regret for the rest of their Miserable Short Lives, for selling for anything less than $100 Per Share - now you know.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 24 at 6:31 PM
$SLS IDMC UNBLINDED ACTUAL MOS AND IR DATA FROM THIS ONGOING P3 INTERIM ANALYSIS - Only inch thick tools don’t get it Now 47 Days since the 78th Event 72nd Dec 26th - 78th May 11 --- 6 Events in 136 Days / Approximately 1 Event Every 22 Days - > Monday was the Bullseye 4 the 80th Event PR. - and the reason the Share Price Launched on each of the Previous Event PR's, is the Same Reason, it will Just about double to $18/ $20 on the 80th. That is - SMART MONEY ... Much Smarter than US ( $ABBV / $RHHBY $BMY) Knows BAT does not offer effective Remission Maintenance - they Know its Gps Doing what its done in all 7 Prior Trials - Prevent Relapse and Extend Survival - Directly Correlated with Immune Response- The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA From the INTERIM ANALYSIS at 60 Events.. penny flipping idiots are going regret for the rest of your Miserable Short Lives, for selling for anything less than $100 Per Share - now you know. https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml
0 · Reply
prismmarketview
prismmarketview Jun. 24 at 6:18 PM
Quantum BioPharma ($QNTM ) is chasing one of the toughest MS problems—actually protecting and repairing myelin—while giants like Novartis ($NVS ), Merck ($MRK ), TG Therapeutics ($TGTX ) and Bristol Myers Squibb ($BMY ) mostly focus on immune modulation. #QNTM #NVS #MRK #TGTX #BMY #MS #biotech https://x.com/PrismMarketView/status/2069847144090231110?s=20
1 · Reply
NetworkNewsWire
NetworkNewsWire Jun. 24 at 1:03 PM
The Quest to Repair What Multiple Sclerosis Takes Away $QNTM $QNTM.CN $NVS $MRK $TGTX $BMY https://ibn.fm/1ChGs
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 24 at 1:47 AM
$BMY Share Price: $55.53 Contract Selected: Jul 17, 2026 $55 Calls Buy Zone: $1.30 – $1.61 Target Zone: $2.09 – $2.55 Potential Upside: 52% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Quantumup
Quantumup Jun. 23 at 7:06 PM
Craig-Hallum⬇️ $MPLT-$40⬅️$43—reit-Buy—said—ML-004 Ph2 IRIS results were mixed but not thesis‍-breaking—missed 1° in social comm—but a meaningful benefit in a defined adolescent subgroup for irritability w/ >tolerability than existing APs $JNJ $BMY - OTSKY DFTX H.C. Wainwright reiterated MapLight Therapeutics Buy; $45 and here is what the analyst had to say: https://x.com/Quantumup1/status/2069496992699437443?s=20
0 · Reply
Mike22332233
Mike22332233 Jun. 23 at 3:07 PM
$SLS A STUNNING PREDICTION ... If the REGAL GPS trial comes in with my estimated HR of 0.27-0.33 (or lower), which would be AMAZINGLY GAME CHANGING ... We will get BO bids (and a bidding war) FROM EACH OF THE FOLLOWING: $MRK $BMY $PFE ABBV RHHBY That's correct ... ALL 5 OF THEM!!! ... Like & FOLLOW ME @Mike22332233 for all developments
0 · Reply
Quantumup
Quantumup Jun. 23 at 2:16 PM
Mizuho⬆️ $CYTK-$118,⬆️aficamten's PoS in nHCM to 90%, reiterated Buy and said: CYTK (OP, increasing PT to $118 from $100): Myqorzo launch tracking ahead of Camzyos (setting up for a great launch) $EWTX TENX $BMY TECX Mizuho added—ACACIA-HCM (nHCM) hit both co-primary endpoints (makes this product even better). We increase our price target to $118 (from $100), primarily driven by aficamten in nHCM — PoS increased to 90% (from 75%) post ACACIA-HCM Ph3 data (hit stat sig on both dual primaries; data overall very consistent across primary/ secondary endpoints). Commercial launch is off to a great start (certainly an area where investors are doing the math to see how 2026 numbers may shake out vs consensus).
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 23 at 3:59 AM
$BMY $PFE $SLS $JNJ 4. My # 1 Suitor for Sellas remains Pfizer followed by close 2nd $BMY 3rd $ABBV and 4Th $JNJ ✌️🙏❤️‍🩹 While Pfizer has made all the right moves in preparation of Sellas BO in January 2026 Pfizer appointed Michael Burns brother of SLS CFO John Burns as Senior Medical Director of Oncology Late Development, coming directly from oncology early development at AbbVie. Someone who spent their career in the belly of the beast understanding exactly how AbbVie develops oncology assets, exactly where the gaps in the Venetoclax franchise are, and exactly what kind of validated late stage asset Pfizer needs to compete in hematologic malignancies just walked through Pfizer's door. Dr. Angelos Stergiou has directly called out Unlike Onureg, GPS does not suppress the bone marrow. This is a critical advantage for AML patients who already have fragile blood counts. AbbVie will be the biggest looser and Ventoclax will be Obsolete. JNJ BOD Katherine Bach connection is compelling. P1 ✌️🙏❤️‍🩹
1 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 22 at 4:15 PM
$SLS $ABBV $PFE $BMY 3 of the most powerful companies in oncology all have specific strategic reasons to own GPS after a positive REGAL readout. BMS needs to protect Onureg. AbbVie needs to protect Venetoclax. Merck needs to extend Keytruda past the patent cliff. And Ptizer just hired people who came from the exact companies that GPS is about to disrupt and know precisely what that disruption is worth. REGAL Phase 3 data after T1 halt= $120.00+ Longs are about to witness the most consequential and contested acquisition it has seen in a generation. Hold with conviction! ✌️🙏❤️‍🩹
0 · Reply
Mike22332233
Mike22332233 Jun. 22 at 11:18 AM
$SLS DID YOU SEE MY STUNNING PREDICTION ... If the REGAL GPS trial comes in with my estimated HR of 0.27-0.33 (or lower), which would be AMAZINGLY GAME CHANGING ... We will get BO bids (and a bidding war) FROM EACH OF THE FOLLOWING: $MRK $BMY $PFE ABBV RHHBY That's correct ... ALL 5 OF THEM!!! ... Like if you agree & FOLLOW ME @Mike22332233 for all new developments
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 22 at 5:26 AM
$SLS $ABBV $RHHBY $BMY 72nd to 78th - 22 Days Per Event - tomorrow its the 44th day since the 78th occurred. IMMINENT Gps is about to get an FDA Green light worth $40B to Big Pharma.
0 · Reply
Mike22332233
Mike22332233 Jun. 22 at 3:08 AM
$SLS A STUNNING PREDICTION ... If the REGAL GPS trial comes in with my estimated HR of 0.27-0.33 (or lower), which would be AMAZINGLY GAME CHANGING ... We will get BO bids (and a bidding war) FROM EACH OF THE FOLLOWING: $MRK $BMY $PFE ABBV RHHBY That's correct ... ALL 5 OF THEM!!! ... Like & FOLLOW ME @Mike22332233 for all developments
0 · Reply